Breakthrough in Malaria Vaccine Pricing: Costs Slashed by Over 50%
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Breakthrough in Malaria Vaccine Pricing: Costs Slashed by Over 50%
-
ナレーター：
-
著者：
このコンテンツについて
Over the past two days, a major announcement has been made regarding the pricing of the world's first malaria vaccine, RTS,S. The vaccine, developed by GSK, the nonprofit organization PATH, and other partners, is set to see its price slashed by more than half. According to a commitment by drugmakers Bharat Biotech and GSK, the cost per dose will drop to less than $5 in endemic countries by 2028. This reduction is made possible through process improvements, expanded production capacity, and cost-effective manufacturing, along with minimal profit margins. The technology transfer of production from GSK to Bharat Biotech, which began in 2021, will be fully realized by 2028, facilitating this price cut[3].
This price reduction is particularly significant given the historical challenges in developing and distributing malaria vaccines. Malaria vaccines have been in development since the 1960s, with substantial progress made in the last decade. The World Health Organization (WHO) recommended the widespread use of the RTS,S/AS01 malaria vaccine among children in sub-Saharan Africa and other regions with moderate to high malaria transmission in October 2021. More recently, the WHO approved a second malaria vaccine, R21/Matrix-M, for use in malaria-endemic countries[5].
In addition to the pricing news, there has been an innovative advancement in vaccine delivery technology. Researchers from Oxford have developed programmable microcapsules that can deliver vaccines in stages, potentially eliminating the need for booster shots. This 'single shot' malaria vaccine delivery system could transform global immunization efforts by simplifying the vaccination process and improving compliance, especially in regions where access to healthcare is limited[1].
These developments come as countries are ramping up their malaria vaccination programs. For instance, Uganda recently launched the largest malaria vaccine introduction to date, targeting 1.1 million children under two years with the R21/Matrix-M vaccine. This vaccine is administered in four doses at 6, 7, 8, and 18 months[4].
The ongoing efforts to enhance malaria vaccination highlight the complex challenges associated with developing vaccines against this parasite. Malaria parasites have a complex life cycle and produce thousands of potential antigens, making it difficult to achieve lifelong protection through vaccination. However, current malaria vaccines, such as RTS,S and R21/Matrix-M, have shown promising results, reducing uncomplicated malaria by around 40%, severe malaria by about 30%, and all-cause mortality by 13%[5].
As these advancements continue to shape the landscape of malaria prevention, they underscore the commitment of global health organizations, researchers, and pharmaceutical companies to combating this persistent and deadly disease.